NDAINJECTIONINJECTABLE
Approved
Jun 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARDUAN (pipecuronium bromide) is a neuromuscular blocking agent administered via injection for use during anesthesia and surgery. It works as a non-depolarizing competitive antagonist at the neuromuscular junction to facilitate intubation and muscle relaxation during surgical procedures. The drug has been in the market since 1990 and faces an approaching loss of exclusivity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating a mature/declining franchise with likely consolidation of the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARDUAN currently has zero linked job openings, reflecting its status as a legacy product approaching loss of exclusivity with minimal active development. Career opportunities on this asset are limited; professionals seeking growth should evaluate products earlier in their lifecycle or those with active clinical pipelines.
Brand ManagerField Sales Representative
Worked on ARDUAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.